MedPath

PFIZER INC.

PFIZER INC. logo
๐Ÿ‡บ๐Ÿ‡ธUnited States
Ownership
Public
Established
1849-01-01
Employees
88K
Market Cap
$163.3B
Website
http://www.pfizer.com

A Multicenter, Open Label Trial To Evaluate Pain Relief With Intravenous Followed By Oral Therapy With Parecoxib/Valdecoxib 40 Mg/Day For Treatment Of Post-Laparoscopic Surgery Pain

Phase 4
Terminated
Conditions
Pain, Post Surgical
Interventions
Drug: parecoxib/valdecoxib
First Posted Date
2008-04-17
Last Posted Date
2008-04-22
Lead Sponsor
Pfizer
Target Recruit Count
4
Registration Number
NCT00660855
Locations
๐Ÿ‡ฆ๐Ÿ‡ท

Pfizer Investigational Site, Buenos Aires, Argentina

A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)

Phase 3
Terminated
Conditions
Generalized Anxiety Disorder
Interventions
Drug: paroxetine
Drug: Placebo
Drug: PD 0332334
First Posted Date
2008-04-15
Last Posted Date
2012-11-16
Lead Sponsor
Pfizer
Target Recruit Count
286
Registration Number
NCT00658762
Locations
๐Ÿ‡ญ๐Ÿ‡บ

Pfizer Investigational Site, Budapest, Hungary

A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)

Phase 3
Terminated
Conditions
Generalized Anxiety Disorder
Interventions
Drug: PD 0332334
Drug: Paroxetine
Drug: Placebo
First Posted Date
2008-04-15
Last Posted Date
2012-11-16
Lead Sponsor
Pfizer
Target Recruit Count
360
Registration Number
NCT00658372
Locations
๐Ÿ‡จ๐Ÿ‡ณ

Pfizer Investigational Site, Tainan, Taiwan

Long Term Use of Somavert (Pegvisomant) For A Regulatory Post Marketing Commitment Plan

Completed
Conditions
Acromegaly
Interventions
First Posted Date
2008-04-15
Last Posted Date
2023-09-25
Lead Sponsor
Pfizer
Target Recruit Count
251
Registration Number
NCT00658879

Long Term Study To Evaluate the Safety, Tolerability and Efficacy of Fesoterodine for Overactive Bladder.

Phase 3
Completed
Conditions
Overactive Bladder
Interventions
First Posted Date
2008-04-15
Last Posted Date
2010-10-13
Lead Sponsor
Pfizer
Target Recruit Count
153
Registration Number
NCT00658684
Locations
๐Ÿ‡ฏ๐Ÿ‡ต

Pfizer Investigational Site, Shibuya-ku, Tokyo, Japan

Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients

Phase 2
Completed
Conditions
Kidney Transplantation
Interventions
First Posted Date
2008-04-15
Last Posted Date
2018-02-23
Lead Sponsor
Pfizer
Target Recruit Count
178
Registration Number
NCT00658359
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Cedars-Sinai Medical Center, Los Angeles, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Ronald Reagan UCLA Medical Center, Los Angeles, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

UCLA Medical Center, Los Angeles, California, United States

and more 61 locations

A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)

Phase 3
Terminated
Conditions
Generalized Anxiety Disorder
Interventions
Drug: Placebo
Drug: PD 0332334
Drug: Paroxetine
First Posted Date
2008-04-14
Last Posted Date
2012-11-16
Lead Sponsor
Pfizer
Target Recruit Count
501
Registration Number
NCT00658008
Locations
๐Ÿ‡ท๐Ÿ‡บ

Pfizer Investigational Site, Khotkovo, Moscow region, Russian Federation

A Double-blind, Double-dummy, Multicenter, Randomized Study of the Efficacy and Tolerability of Valdecoxib 40 mg Versus Rofecoxib 50 mg in Treating the Symptoms of Ankle Sprain

Phase 4
Terminated
Conditions
Acute Pain
Interventions
First Posted Date
2008-04-14
Last Posted Date
2018-11-30
Lead Sponsor
Pfizer
Target Recruit Count
45
Registration Number
NCT00657449
Locations
๐Ÿ‡ง๐Ÿ‡ท

Instituto Ortopedico de Goiania, Goiania, Goias, Brazil

๐Ÿ‡ง๐Ÿ‡ท

Grupo Hospitalar Conceiรงao, Porto Alegre, RS, Brazil

๐Ÿ‡ง๐Ÿ‡ท

Hospital Geral do Grajau, Sรฃo Paulo, SP, Brazil

and more 5 locations

A Double-blind, Parallel Group, Placebo-Controlled Outpatient Trial of PD 00200390 in Adults With Nonrestorative Sleep

Phase 2
Completed
Conditions
Nonrestorative Sleep
Interventions
Drug: PD 0200390
Drug: Placebo
First Posted Date
2008-04-09
Last Posted Date
2012-07-25
Lead Sponsor
Pfizer
Target Recruit Count
306
Registration Number
NCT00655369
Locations
๐Ÿ‡จ๐Ÿ‡ฆ

Pfizer Investigational Site, Toronto, Ontario, Canada

Prophylaxis In Venous Thromboembolism In Primary Care, A Pilot Study

Phase 4
Terminated
Conditions
Thromboembolism
Deep Vein Thrombosis
Dalteparin
Interventions
First Posted Date
2008-04-09
Last Posted Date
2008-09-29
Lead Sponsor
Pfizer
Target Recruit Count
8
Registration Number
NCT00655122
Locations
๐Ÿ‡ช๐Ÿ‡ธ

Pfizer Investigational Site, Torremolinos, Spain

ยฉ Copyright 2025. All Rights Reserved by MedPath